The University of Virginia Comprehensive Cancer Center) seeks adults ages 18 and over with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) for a research study. The purpose of the study is to compare the usual treatment for NSCLC to a study treatment that combines the drugs ramucirumab and pembrolizumab. The combination of ramucirumab and pembrolizumab is not approved by the FDA to treat advanced lung cancer. Participants in this study will be randomly selected to continue with the usual treatment for NSCLC or receive the investigational drugs.
The study involves receiving the usual treatment or the investigational drugs, as well as coming in for study visits, which include exams, laboratory tests, and procedures such as having your blood drawn, and talking to the study doctor. Participation includes a treatment period, which includes receiving the investigational drugs every 21 days for up to 2 years, and a follow up period for up to 3 years.
Participant’s insurance company will be billed for medication, tests and procedures. The investigational drugs, pembrolizumab and ramucirumab, will be provided for at no cost to the participant or their insurance company.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05633602